Clinical Trial Update: A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) [Phase 3]

View source ↗

Summary

This clinical trial update describes ACE-LY-312, a Phase 3 study evaluating acalabrutinib in combination with R-CHOP for previously untreated non-GCB diffuse la…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Adriamycin (doxorubicin)
• CALQUENCE (ACALABRUTINIB)
• Cytoxan (cyclophosphamide)
• Deltasone (prednisone)
• Oncovin (vincristine)
• Rituxan (rituximab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING